ACACR NewsLetter

Association of Chinese Americans in Cancer Research

Volume 1
Issue 5
January 2019



Liu Y et al. *Nat Commun*, 2018

Contact
acacrnews@gmail.com

In This Issue

ACACR 2019
New Year's Greeting

------Zhenkun Lou

Dear colleagues and friends,

Happy New Year! Over the past years, with the leadership of our past president, Dr. Shi-Yuan Cheng, we have made great progresses for the mission of our organization. We have inaugurated our organization, and held two successful annual meetings with hundreds of participants. We have also nominated our colleagues to AACR sub-committees and journal editorial boards. Furthermore, in partner with Chongqing Medical University, ACACR will have an official affiliated journal: Genes and Diseases, under the leadership of Drs. Tongchuan He and Zhenghe Wang.

In addition to these laudable achievements, we still face several challenges. We need more colleagues to join the ACACR membership and participate in the ACACR activities. There is strength in numbers! United, we can make powerful pushes for the interests of our community in cancer research fields. Currently, the political environment for Chinese American scientists is challenging. We need more Chinese American scientists to step into leadership position in professional organizations for cancer research. We will keep working with AACR and other societies to promote Chinese American scientists in cancer research.

Finally, we warmly welcome everyone to attend the 3rd ACACR annual meeting at the 110th AACR in Atlanta in April, 2019. It is an exciting time for cancer research with many game-changing therapies, such as cancer immunotherapy, and many scientists in our community have made critical contributions. What we do matters! May each of you have a prosperous and productive 2019!

Genes & Diseases became an ACACR affiliated journal

------Zhenghe John Wang

Here comes, Genes & Diseases, the official journal of ACACR! Here comes, the voice of ACACR!

With the support of the ACACR leadership and Dr. T.C. He, Editor-in-Chief of the journal, ACACR decided to join forces with Elsevier Publication and Chongqing Medical University to run Genes & Diseases. From ACACR's prospective, our missions are to use the journal as a platform to promote Chinese American Scientists, to highlight exciting researches published by the ACACR members, and to publish high quality research articles. Our goals are to make the impact factor of the journal ~ 8 in three years and greater than 10 in five years. While these goals are ambitious, I strongly believe that with the support of all ACACR members we can certainly achieve them! Our initial focus is to publish high quality review articles. Once the impact factor reaches 7 or 8, we will invite ACACR members to submit their high quality research papers. Here, I'd like to take this opportunity to thank the ACACR members who have committed to contribute a review paper to the journal! I'd also like to thank these who agreed to serve on the editorial board.

A thousand miles starts with the first step! We have already taken action. When the 2018 Nobel Prize in Physiology or Medicine was announced, we published a commentary by Dr. Xingxing Zang, a former postdoc from James Allison's laboratory, in Genes & Diseases online within a week of the announcement. In the current issue, we have two review articles contributed by ACACR members. We also published research highlights of ACACR members.

Genes & Diseases is currently indexed in ESCI and PubMed. It has a CiteScore (equivalent to impact factor) of 4.74 in 2017, and is expected to surpass 5.0 in 2018. Nonetheless, Year 2019 will be critical to the journal, as we need to push it to become a science citation indexed (SCI) journal. Here I urge all of you to support the journal, because it is our journal! You can help in many ways including, but not limited to, contributing review articles, reviewing manuscripts and citing the papers published in the journal. Together we can make Genes & Diseases a great success! As a Deputy Editor-in-Chief of the journal, I am here to serve you all. I look forward to working with you!



https://www.sciencedirect.com/journal/genes-and-diseases

CALL FOR PAPER!

RESEARCH HIGHLIGHTS

Zhenkun Lou lab at Mayo Clinic published that ZNF506-dependent positive feedback loop regulated H2AX signaling after DNA damage. The results demonstrate how the DDR pathway is orchestrated by ZNF506 to maintain genomic integrity.
https://www.nature.com/articles/s41467-018-05161-0

Li Ma lab at MD Anderson Cancer Center demonstrate that MALAT1 is a metastasis-suppressing lncRNA rather than a metastasis promoter in breast cancer, calling for rectification of the model for this highly abundant and conserved lncRNA.
https://www.nature.com/articles/s41588-018-0252-3

Zhe-Sheng Chen lab at St. John's University published that Regorafenib antagonized BCRP-mediated multidrug resistance in colon cancer. https://www.ncbi.nlm.nih.gov/pubmed/30392788. In addition, his lab reported that immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer both in vitro and in vivo. https://www.ncbi.nlm.nih.gov/pubmed/30391357. Moreover, his lab found that Selonsertib (GS-4997) as an ASK1 inhibitor can antagonize multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. https://www.ncbi.nlm.nih.gov/pubmed/30315846

RESEARCH HIGHLIGHTS

Shuli Xia lab at Johns Hopkins University School of Medicine identified YAP and its downstream signaling pathway Notch mediating the cell growth-inhibiting effect of IDH1R132H/WT.
https://www.nature.com/articles/s41388-018-0334-9
In another recent publication, her team found that KLF4 bound to methylated CpGs at the enhancer regions of the B-cell lymphocyte kinase (BLK) and Lim domain only protein 7 (LMO7) genes, and activated their expression via 3D chromatin loop formation with their promoter regions.
https://www.tandfonline.com/doi/full/10.1080/15592294.2018.1504592

Jianwen Que Lab at Columbia University published that 3D modeling of esophageal development using human PSC-derived basal progenitors reveals a critical role for notch signaling.
https://www.ncbi.nlm.nih.gov/pubmed/30244870

Hui-Kuan Lin lab at Wake Forest School of Medicine revealed that AMPK plays critical role in driving Akt activation under stress, tumorigenesis and drug resistence.
https://www.nature.com/articles/s41467-018-07188-9

RESEARCH HIGHLIGHTS

Deyu Fang lab at Northwestern University and **Kezhong Zhang** lab at Wayne State University School of Medicine as well as others recently published that HRD1-ERAD controls production of the hepatokine FGF21 through CREBH polyubiquitination. http://emboj.embopress.org/content/37/22/e98942.full. In addition his lab and his collaborators also published that the ER-associated ubiquitin ligase HRD1 can program liver metabolism via targeting multiple metabolic enzymes. https://www.nature.com/articles/s41467-018-06091-7. Moreover, his lab reported that ubiquitin-specific peptidase 22(USP22) deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism. https://www.ncbi.nlm.nih.gov/pubmed/29844011

Xiongbin Lu lab at MD Anderson and **Xinna Zhang** lab at Indiana University School of Medicine published that heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. https://www.nature.com/articles/s41467-018-06811-z

Xinna Zhang lab at Indiana University School of Medicine published that targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. https://www.nature.com/articles/s41467-018-07264-0

RESEARCH HIGHLIGHTS

Chuan He lab at University of Chicago found that N6-methyladenosine (m6A) facilitates hippocampus-dependent learning and memory through YTHDF1, a m6A binding protein that enhances protein synthesis in a neuronal-stimulus-dependent manner. https://www.nature.com/articles/s41586-018-0666-1

Zui Pan lab at University of Texas at Arlington published that targeting Orai 1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma. https://www.ncbi.nlm.nih.gov/pubmed/29908962

David Z. Qian lab at Oregon Health & Science University published that interplay between hypoxia and androgen/AR-targeted therapy. https://www.nature.com/articles/s41467-018-07411-7

Wenyi Wei lab at Harvard Medical School discovered that SPOP promotes Nanog destruction to suppress stem cell traits and prostate cancer progression. https://www.sciencedirect.com/science/article/abs/pii/S1534580718310189. His group with others also found that SCF^{FBW7}-mediated degradation of Brg1 suppresses gastric cancer metastasis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120942/pdf/41467_2018_Article_6038.pdf

RESEARCH HIGHLIGHTS

Qiang Shen lab at MD Anderson published that activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. https://www.nature.com/articles/s41388-018-0340-y

Peiqing Sun lab at Wake Forest School of Medicine published that miR-30 disrupts senescence and promotes cancer by targeting both $p16^{INK4A}$ and DNA damage pathways.
https://www.nature.com/articles/s41388-018-0358-1

Ming Tan lab at Mitchell Cancer Institute found that Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation.
https://www.nature.com/articles/s41388-018-0407-9

Gang Zhou lab at Georgia Cancer Center published that alternation of tumor metabolism by CD4+ T cells leads to TNF-α-dependent intensification of oxidative stress and tumor cell death.
https://www.ncbi.nlm.nih.gov/pubmed/29887396

Lizi Wu lab at University of Florida published that INSL4 signaling plays important role in sustaining the growth and viability of LKB1-inactivated lung cancer.
https://www.ncbi.nlm.nih.gov/pubmed/30423141

RESEARCH HIGHLIGHTS

Zhishan Wang lab at University of Kentucky published that in vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
https://www.ncbi.nlm.nih.gov/pubmed/30352320
In another recent paper, they reported that miR-205 down-regulating intergrin α5 suppressed triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
https://www.ncbi.nlm.nih.gov/pubmed/29964204

B. Hilda Ye lab at Albert Einstein College of Medicine found that North American Adult T-cell leukemia lymphoma (ATLL) has a distinct mutational and transcriptional profile and responds to epigenetic therapies.
https://www.ncbi.nlm.nih.gov/pubmed/30104217

Lin Zhang lab at UPMC Hillman Cancer Center discovered that the induction of p53 up-regulated modulator of apoptosis (PUMA) mediated acetaminophen-induced necrosis and liver injury.
https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.30422
His lab also reported that Mcl-1 phosphorylation without degradation mediated sensitivity to HDAC inhibitors by liberating BH3-only proteins.
http://cancerres.aacrjournals.org/content/78/16/4704.full-text.pdf

2018 2019

RESEARCH HIGHLIGHTS

Jianhua Yu lab at The Ohio State University Comprehensive Cancer Center published that the IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells. https://www.nature.com/articles/s41590-018-0265-1. In another recent paper his lab reported that fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells.
https://www.ncbi.nlm.nih.gov/pubmed/29666301
Moreover, they found that an oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma.
https://www.nature.com/articles/nbt.4302
Also, they demonstrate that SMAD4 promotes TGF-β-independent NK cell homeostasis and maturation and antitumor immunity.
https://www.jci.org/articles/view/121227/pdf

Li-Shu Wang lab at Medical College of Wisconsin discovered that loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors.
https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.31366

Zhang Qing lab at Lineberger Comprehensive Cancer Center published that VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
http://science.sciencemag.org/content/361/6399/290/tab-pdf

RESEARCH HIGHLIGHTS

Pan Zheng lab at University of Maryland Baltimore School of Medicine recently reviewed how does an anti-CTLA-4 antibody promote cancer immunity. https://www.cell.com/trends/immunology/pdf/S1471-4906(18)30193-5.pdf

Xiaobo Zhou lab at The University of Texas Health Science Center at Houston published that alternative splicing links histone modifications to stem cell fate decision. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1512-3

Qiufu Ma lab at Dana-Farber Cancer Institute identified the pathways required for coping behaviours associated with sustained pain. These studies reveal a fundamental subdivision within the cutaneous somatosensory system that consists of separate pathways for driving reflexive defensive versus coping responses. https://www.nature.com/articles/s41586-018-0793-8. His group also discovered timing mechanisms underlying gate control by feedforward inhibition. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309466/

2018 2019

RESEARCH HIGHLIGHTS

Haifeng Yang lab at Thomas Jefferson University, **Qin Yan** lab at Yale University**, and Yanmin Xu** lab at Vanderbilt University Medical Center discovered that multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer.
https://elifesciences.org/articles/37925

Zigang Dong lab with others found that gossypetin is a novel MKK3 and MKK6 inhibitor that suppresses esophageal cancer growth in vitro and in vivo. Their findings suggest that gossypetin is an MKK3 and MKK6 inhibitor that could be useful for preventing or treating esophageal cancer.
https://www.ncbi.nlm.nih.gov/pubmed/30391783

Erxi Wu lab at Baylor Scott and White Health (BSWH) with **Jason H. Huang** lab at BSWH identified a panel of genes as a prognostic biomarker for glioblastoma. Their results provide important new insights into the early diagnosis and the prognosis for glioblastoma patients and introduce potential targets for glioblastoma therapeutics.
https://www.sciencedirect.com/science/article/pii/S2352396418304353?via%3Dihub

RESEARCH HIGHLIGHTS

Cheng Cheng Zhang lab at University of Texas Southwestern Medical Center and **Zhiqiang An** lab and **Ningyan Zhang** lab at University of Texas Health Science Center discovered that LILRB4 orchestrates tumour invasion pathways in monocytic leukaemia cells by creating an immunosuppressive microenvironment. They conclude that LILRB4 represents a compelling target for the treatment of monocytic AML.
https://www.nature.com/articles/s41586-018-0615-z

Hui Li lab at University of Virginia published a paper regarding the landscape and implications of chimeric RNAs in cervical cancer. They have shown that highly frequent chimeric RNAs are present in cervical cancers.
https://www.sciencedirect.com/science/article/pii/S2352396418304778?via%3Dihub#!

Howard Y. Chang lab at Stanford University investigated the chromatin accessibility landscape of primary human cancers. Their discovery of hundreds of noncoding somatic mutations that exhibit allele-specific regulatory effects suggests a pervasive mechanism for cancer cells to manipulate gene expression and increase cellular fitness.
http://science.sciencemag.org/content/362/6413/eaav1898.long

RESEARCH HIGHLIGHTS

Calvin J. Kuo lab at Stanford University School of Medicine found that organoid-based propagation of primary tumor epithelium en bloc with endogenous immune stroma should enable immuno-oncology investigations within the TME and facilitate personalized immunotherapy testing.
https://www.sciencedirect.com/science/article/pii/S0092867418315137?via%3Dihub#!

Mien-Chie Hung lab at the University of Texas MD Anderson Cancer Center discovered that targeting PKCδ as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in EGFR-mutant lung cancer.
https://www.sciencedirect.com/science/article/pii/S1535610818305282?via%3Dihub#!

Catherine J. Wu lab at Dana-Farber Cancer Center published a paper on immunotherapy for glioblastoma: going viral. They claimed that intratumoral infusion of a nonpathogenic replication-competent recombinant polio-rhinovirus chimera for recurrent glioblastoma demonstrates safety and promising preliminary treatment responses.
https://www.nature.com/articles/s41591-018-0142-3

MEMBERS' ACHIEVEMENTS

Congratulations to Dr. Ruiwen Zhang who is recently named as **Fellow of National Academy of Inventors**.

http://www.uh.edu/news-events/stories/2018/december-2018/121118-zhang-nai-fellow.php

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

Postdoctoral Researcher

Dr. Jing Wang (https://medicine.osu.edu/cancer-biology-genetics/directory/faculty/wang-jenny-phd/pages/index.aspx), a professor at Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center invites applications for full-time researchers at the level of Postdoctoral Researcher. We are looking for scientists with a doctoral degree, outstanding academic credentials and a record of scholarly productivity in the areas of tumor biology, immunology and genetics. Successful candidates will conduct research to determine molecular mechanisms of colon cancer metastasis, tumor dormancy and drug resistance, identify and validate novel targets using 2D- and 3D- cell cultures, mouse models and PDXs, and ultimately develop effective therapies to treat colon cancer patients. The Ohio State University offers a competitive salary and outstanding benefits.

The Ohio State University is one of the largest public universities with 200+ academic majors, significant physical and interdisciplinary interactions between the Colleges of Arts and Sciences and Medicine. This is complemented by an outstanding Comprehensive Cancer Center, which provides the infrastructure and resources for strong interdisciplinary interactions with a focus on translation, in a collegial and supportive research environment. The university is located in Columbus, a vibrant and rapidly developing city of almost one million, which is recognized by Money Magazine as one of the “6 best big cities” in the US.

The Ohio State University is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status or protected veteran status.

Applications should include *Curriculum Vitae*, Research Summary, and contact information for three academic references and be sent to jing.wang@osumc.edu.

Can also apply online at http://wexnermedical.osu.edu/careers. Enter keyword or job ID# 441194 to review the job posting for Post-Doctoral Researcher.

Postdoctoral position, LSUHSC Shreveport

A postdoc position is available in the Department of Biochemistry & Molecular Biology at LSUHSC Shreveport to study prostate cancer. Ph.D. degree and a background in cancer biology are required. Contact Xiuping Yu at xyu@lsuhsc.edu.

Under moderate supervision, this individual is expected to perform mammalian cell culture and transfection, establish stable cell lines for gene over-expression or knockdown, conduct biochemical assays, maintain records for experiments and procedures, and appropriately analyze data and report finding. After training, this individual is also expected to maintain mouse colony and husbandry, perform small animal surgeries, collect tissues from mice, and conduct IHC.

Postdoctoral Research Associate, St. Jude Children's Research Hospital

Summary
The laboratory of Dr. Taosheng Chen studies the transcriptional regulation of nuclear receptors and drug–metabolizing enzymes and their roles in tumorigenesis and cancer drug resistance. We use large-scale approaches to investigate signaling pathways, identify and validate targets, develop novel chemical probes/therapeutic leads by using a multidisciplinary approach, and use them to interrogate the function of PXR, CAR and CYP3A in order to overcome drug resistance and tumorigenesis in cellular and animal
models (*Lin et al,* ***Nat Commun.*** *8:741, 2017*).

Responsibilities
The postdoctoral fellow will investigate the molecular mechanisms (transcription and/or alternative splicing) responsible for the aberrant expression of CYP3A in extrahepatic cancers The Chen Lab provides a unique training environment. In addition to basic research, the postdoctoral fellow will learn and gain experience in small molecule drug discovery from target identification, compound screening to preclinical studies. Former Chen Lab postdocs have landed jobs as Assistant Professors in Universities or Senior Scientist in Pharmaceutical Companies.
The successful candidate will work in a collaborative and multidisciplinary environment by collaborating with biologists, chemists and structural biologists (https://www.stjude.org/chen).

Minimum Education
Highly motivated individuals with a strong publication record are encouraged to apply. Strong background in cell biology and molecular biology, and significant experience in transcriptional regulation and/or mRNA splicing are desirable. Candidates must have a PhD degree.

Contact Information
Taosheng Chen, PhD
Member (Professor), Department of Chemical Biology and Therapeutics
St. Jude Graduate School of Biomedical Sciences
Director, High Throughput Bioscience Center
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-2794, USA
Phone: 1-901-595-5937
Fax: 1-901-595-5715
Email: taosheng.chen@stjude.org
Website: http://www.stjuderesearch.org/chen/

Senior Research Technologist, St. Jude Children's Research Hospital

The High-Throughput Bioscience (HTB) Center under Director and St. Jude Faculty Member Taosheng Chen, PhD, seeks a Senior Research Technologist to implement projects and present and publish research results. The ideal candidate will be able to function autonomously, leading projects themselves, as well as a part of a team that will contribute to the function of the HTB Center. The Center consists of those with advanced training in biology, chemistry, and engineering who work together on multiple techniques including target identification and validation, assay development, highthroughput screening, laboratory automation, and management of scientific collaborations.

The successful candidate will be experienced in cell-based assay development and have experience in any of the following areas: cell-based high-throughput and highcontent screening, using 3D (such as organoids and spheroids) or co-culture models, using instruments (such as flow cytometer or imager), and molecular biology. In lieu of experience, a motivated recent PhD graduate with a strong publication record will be considered.

The HTB Center emphasizes motivation and dedication to the development of drug discovery technologies and prepares and trains members of its team well for growth within the St. Jude organization or qualified training for the pharmaceutical industry.

Please direct your questions, cover letter, current CV, and 3 letters of reference to Dr. Taosheng Chen (taosheng.chen@stjude.org).

Contact
Taosheng Chen, PhD
Member, Department of Chemical Biology and Therapeutics
Director, High Throughput Bioscience Center
St. Jude Children's Research Hospital
Memphis, TN 38105-3678, USA
https://www.stjude.org/chen
http://www.stjuderesearch.org/site/lab/chen

Weill Cornell Medicine
Cornell University

Postdoctoral Fellow in Cornell Medical College, NY

A postdoc fellow position is available in Dr. Nancy Du's laboratory (www.nancydu.net) in Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University. The main research focus in the Du laboratory is to understand the molecular mechanisms of cancer metastasis using mouse models and to develop novel therapeutics.

The position is open to graduating PhD or MD/PhD students and current postdoctoral fellows with less than three years of postdoctoral experience. High levels of critical thinking, strong technical skills, and recent first author publications in high impact journals are required.

Candidates should have strong organizational, written, and verbal communication skills. They should have the ability to work both independently and as part of our research team. The position offers competitive salary and the exposure to a dynamic and vibrant scientific environment at Weill Cornell Medicine, Rockefeller University, and Memorial Sloan Kettering Cancer Center in the New York City area.

To apply, please send a cover letter with a brief summary of research experience and interests, CV, the contact for 3 references, and publications in one PDF file to

Yi-Chieh Nancy Du, Ph.D.
Associate Professor
Department of Pathology and Laboratory Medicine
Weill Cornell Medical College
1300 York Avenue, Box 69
New York, NY 10065
email: **nad2012@med.cornell.edu**

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

Postdoctoral positions (RNA and metastasis research) at MD Anderson Cancer Center

Postdoctoral Fellow positions are available in Dr. Li Ma's laboratory at MD Anderson Cancer Center (https://faculty.mdanderson.org/profiles/li_ma.html). Since its founding in 2010, the Ma Lab has played a major role in establishing models of microRNA-mediated regulation of metastasis, epithelial-mesenchymal transition, and therapy resistance (Nature Medicine 2012, PLoS Genetics 2014, Nature Communications 2014, Cancer Research 2016, etc), and in rectifying models of long non-coding RNA (lncRNA) regulation of metastasis (Nature Genetics 2018 – a paradigm-shifting study that establishes the framework for rigorous characterization of lncRNAs). In addition to RNArelated research, the Ma Lab also discovered the deubiquitinases for key cancer proteins; some of these deubiquitinases are promising anti-tumor and anti-metastatic targets (Nature Cell Biology 2013, Nature Cell Biology 2014, Cell Reports 2018, Nature Communications 2018, etc). Our work has been confirmed and cited by many groups (Dr. Ma's Google Scholar citations: 10,000 as of 2018). Multiple former postdocs from this lab have landed independent faculty positions. Current interests include: (1) establishing new paradigms for RNA functions and mechanisms in tumor progression and metastasis; (2) screening for deubiquitinating enzymes that promote tumorigenesis, metastasis, or therapy resistance; and (3) investigating novel regulators and regulations of tumor radioresistance, drug resistance, and anti-tumor immunity. We consider highly motivated and creative candidates with a recently obtained Ph.D. degree and strong first-author publications. For those interested, please send a CV, three letters of recommendation, and a research statement (limalab2018@gmail.com).

RUTGERS
Cancer Institute
of New Jersey

Postdoctoral positions at Rutgers Cancer Institute of New Jersey/Rutgers University

Two postdoctoral positions supported by newly-funded NIH R01 grants are available for a highly motivated individual at Rutgers Cancer Institute of New Jersey/Rutgers University. The research interest of our lab is to study the development and progression of cancer, including cancer metastasis, cancer metabolic reprogramming and tumor microenvironment. Specific research directions in the lab include: 1) the regulation and function of tumor suppressor p53 and its gain-of-function mutants in cancer; 2) p53 and other tumor suppressors in tumor microenvironment and tumor immunology. (Nature Communications, 4:2935; 4:2996; 5:5218; 8:1823; Genes Dev, 30:1956; 31: 1641; eLIFE, 4:e08401; 5:e10727; 7:e34701). Candidates should have a recent Ph.D. Degree and strong background and skills in molecular biology and/or cancer biology. Rutgers Cancer Institute of New Jersey/Rutgers, State University of New Jersey is a National Cancer Institute designated comprehensive cancer center. The salary and benefit will follow the NIH postdoctoral fellow standard. Applicants should send a CV and names of three references by email to: Wenwei Hu, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903. E-mail: wh221@cinj.rutgers.edu

How to become a member of ACACR
如何成为ACACR 协会会员

感谢大家对ACACR 的关心和鼓励，更感谢许多志愿者们的付出。我们的财务李勇已把协会的银行帐户，PayPal 帐户开好；我们 IT 小组的戴木水已经将网上自动付款体系建成；我们会员小组的席亚光已将会员注册的表格等设计好。下面是如何成为我们协会成员了。

我们有两种会员制，普通会员 (regular member) 和 临时会员 (associate member)。普通会员又分终生会员 (lifetime membership) 以及年度会员， 前者会费 $500, 后者会费每两年$100。临时会员暂不收费，但以后可能会有所改变。

目前我们还是半自动化注册 (即有部分是手工)。请到我们网站 acacr.org 在“membership”栏下载注册表, 填好后电邮给表最后的邮件地址。

我们共有三种付会员费的方式：

1. 在我们网站上用Paypal或信用产卡付。tacacr@outlook.com

2. 银行直接转帐. Routing No: 044000037, Account No: 121901257.

3. **支票**. 请写明付给 "Association of Chinese Americans in Cancer Research, Inc." **需要**邮**寄支票的**, 请与Shuli 联系, xia@kennedykrieger.org. 请在电邮上注明 ACACR member.

我们将在收到付款后五-七个工作日发出收据。

协会会员的益处:

协会普通会员和临时会员都可以参加WeChat 的讨论，信息交流，年会以及其他一些由ACACR 组织的活动。普通会员还有以下一些额外的福利。

（1）协会内部选举和被选举权;

（2）由ACACR 推荐去AACR 各种委员会和杂志编辑部;

(3）在我们协会网站上招人广告栏上发广告(微信群里的帖子会很快被淹没);

（4）在我们协会网站上贴一些会议通知;

（5）**在我**们协会每月一次的 Newsletter **上登广告** (非会员收费 $20);

（6）**我**们协会网站和 Newsletter “Research Highlights" 栏目中将优先选发协会会员刚发表的文章;

（7）今后ACACR 有小型奖励机会 (award opportunity), 将优先考虑我们的普通会员;

（8) 今后购买ACACR 赞助商的物品时可能有折扣机会。

普通会员今后可能有的福利还包括会员学术交流活动 (annual retreat), 成员互助等。

ACACR thanks the sponsors

Gold Sponsors

Tanon (biotanon.com)

Tanon 天能®

领先的制造商与解决方案提供商

biotanon.com

Silver Sponsors

Medchemexpress, NJ (medchemexpress.com)

MCE®

MedChemExpress

Bronze/event Sponsors

Alphacait (alphacait.com)

ALPHACAIT